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An ever-increasing body of evidence has been published
over the last two decades providing the ground based on
which nuclear cardiology is now an accepted well-validated,
cost-effective non-invasive imaging tool for the diagnostic
and prognostic assessment of coronary artery disease.
Nevertheless, the number of myocardial perfusion imaging
(MPI) studies performed in Europe is low not only compared
with the number of MPI performed in the USA, but also
from that which would be expected on the basis of epide-
miological data. A recent survey on the regulatory back-
ground of nuclear cardiology in Europe [1] performed by
the European Council of Nuclear Cardiology (ECNC, http://
www.ecnc-nuclearcardiology.org/index.php) has pointed
out several issues, which may contribute to this situation.
In Europe, Nuclear Medicine is a restricted and closely
regulated specialty, which on one hand guarantees the
quality and safe use of radionuclide. On the other hand,
however, it may limit integration of Nuclear Cardiology into
the clinical cardiology arena. In fact, cardiologists need to be
more involved in nuclear cardiology, otherwise the demon-
stration that MPI is of clinical value may remain of academic
interest. With regards to MPI positron emission tomography
(PET) scanning, the situation is even more worrying. Although
with the widespread use of oncology PET scanning the
availability of scanners has dramatically increased, this has
not yet caused a substantial rise in cardiac PET scanning. An
ideal flow tracer should be readily available, have a short
half-life for repeat rest and stress MPI with negligible
waiting time, have a linear extraction rate over a wide range
of flow independent of metabolism and deliver low radiation
to patient and staff. Although 15O-labelled water may appear
closest to such ideal properties, its clinical use is prevented
by the fact that it requires high-end post processing as it does
not provide clinically useful images. 13N-ammonia is an
excellent alternative allowing to obtain images similar to
SPECT because this compound is accumulated into myo-
cardial cells by linear extraction over an acceptably wide
range of flow. However, both compounds are limited by the
fact that they require an on-site cyclotron due to the short
half-life of the isotope (9.8 min for 13N; 2 min for 15O).
By contrast, 82-rubidium is a generator-produced tracer,
which may meet several requirements of an ideal tracer,
including short half-life, short scan time allowing high
troughput. Unfortunately, this is also reflected by the short
half-life of the generator, which needs to be changed after
about 4 to 6 weeks, rendering this technique relatively ex-
pensive. In addition, the advantage of a generator, i.e. the fact
that there is no need for a cyclotron, is presently often coun-
terbalanced by the fact that satellite PET-centres without
cyclotron typically get 18F compounds, mostly fluorodeoxy-
glucose (FDG), from a distant cyclotron. Thus, for pure
logistic reasons the priority so far remained on FDG
scanning as FDG has to be used without delay upon deliv-
ery, and cardiac scans may be done in the limited remaining
slots for example at the end of the FDG program.
In the present issue of the European Journal of Nuclear
Medicine and Molecular Imaging, Groves et al. have
reported on their initial experience using 82-Rubidium
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PET for replacing clinical SPECT myocardial perfusion
imaging (MPI) [2]. Image quality was assessed by five
nuclear medicine physicians and judged good in 77% and
adequate in 23% despite the fact that BMI was over 30 kg/m2
in 49% of the patients. The diagnostic accuracy was docu-
mented by the fact that 93% of the findings were consistent
with the coronary angiography, which was however only
available in a third of the study population.
The first 82-Rubidium generator has been described in
1981 [3]. The first studies on the clinical utility of 82-
Rubidium myocardial perfusion scanning have been reported
more than two decades ago [4], but its prognostic value has
been fully established only recently [5]. Although 82-
Rubidium is now widely used in the US, this tracer has had
no commercial success in Europe so far. With this regard, the
authors mention in their discussion that 82-Rubidium gener-
ator is relatively cheap (in the region of 25,000 Euros), but it is
quite clear that such a price can only be called cheap in
relation to a very high number of scans. In fact, 82-Rubidium
is not only most suited for a high-volume clinical service
technically, but its use also economically favours large
volume centres as obviously the price of the generator—as
opposed to the expensive use of a cyclotron—is independent
of the number of the tracer administration.
Every effort should be made by the industry to minimize
the price of the generator, so that not only in large Nuclear
Cardiology Services—where a PETor PET/computed tomog-
raphy (CT) scanner can be exclusively dedicated to cardiac
scanning—82-Rubidiummay finally facilitate a breakthrough
of cardiac PET MPI scanning for clinical routine in Europe.
Unfortunately, the present study was restricted to relative
flow imaging, although the use of list mode acquisition (not
available from the start of the study) would offer the oppor-
tunity to calculate flow and flow reserve, which represents
one of the big advantages over SPECT. In addition, the
authors’ approach to use the 16-slice CT only for attenua-
tion correction does not take full advantage of the inte-
grated scanner capabilities, although many readers would
have expected new insights into hybrid imaging [6] after
reading cardiac PET/CT in the title.
Nevertheless, and although the use of 82-Rubidium has
been already described in a number of reports in the literature,
the merit of the present study is that it encourages us to benefit
from the substantial superiority of PET technique over
SPECT, as the transition from SPECT to 82-Rubidium appears
easy even from the start, resulting in good image quality even
in obese patients. The superiority over SPECTcan be expected
regarding accuracy, study duration, staff radiation exposure,
reduced patient dose, patient discomfort and potentially
economic benefit. These are all important implications, which
may not have been fully appreciated in Europe so far. The
article by Groves et al. may aid awareness of this.
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